


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 8. (Cancelled).

9. (New) A compound of formula (I):



wherein

R¹ represents aryl or heteroaryl;

R² represents C₁₋₆ alkyl or C₃₋₈ cycloalkyl;

R^{2a} represents hydrogen, halogen, C₁₋₃ alkyl, or C₁₋₃ alkoxy;

n represents 0, 1, or 2;

A represents -C(H)=, -C(R^{2b})=, or -N=;

R^{2b} represents C₁₋₃ alkyl, C₂₋₄ alkenyl, halogen, C₁₋₃ alkoxy, amino, cyano, or hydroxy;

B represents -C(R³)= or -N=;

R³ represents hydrogen, halogen, optionally substituted C₁₋₆ alkyl, C₂₋₆ alkenyl, aryl, heteroaryl, heterocyclil, -C₁₋₆ alkyl-aryl, -C₁₋₆ alkyl-heteroaryl, -C₁₋₆ alkyl-heterocyclil, -C₂₋₆ alkenyl-aryl, -C₂₋₆ alkenyl-heteroaryl, -C₂₋₆ alkenyl-heterocyclil, C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, cyano, azido, nitro, sulphoxide, -NR⁷R⁸, -NR⁹COR¹⁰, -

NR¹¹SO₂R¹², -NR¹¹CO₂R¹², -OR¹³, -SO₂R¹⁴, -SR¹⁵, -C≡CR¹⁶, -C₀₋₆ alkyl-(CF₂)_qCF₃, -

CONR¹⁷R¹⁸, COOR¹⁹, -C₁₋₆ alkyl-NR²⁰R²¹, -C₁₋₆ alkyl-N₃, or R³ together with R^{2b} on

adjacent carbon atoms may form a fused 5-7 membered saturated or partially

saturated carbocyclic or heterocyclic ring optionally substituted by a C₁₋₆ alkyl group;

R⁴ represents optionally substituted C₁₋₆ alkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-aryl, -C₁₋₆ alkyl-heteroaryl, or -C₁₋₆ alkyl-heterocyclil;

R⁵ represents hydrogen, optionally substituted C₁₋₁₀ alkyl, -C₃₋₈ cycloalkyl, -C₃₋₈ cycloalkenyl, aryl, heteroaryl, heterocyclil, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, -C₃₋₈ cycloalkyl-aryl, -heterocyclil-aryl, -C₁₋₆ alkyl-aryl-heteroaryl, -C(R^aR^b)-CONH-C₁₋₆ alkyl, -C(R^cR^d)-CONH-C₃₋₈ cycloalkyl, -C₂₋₆ alkyl-S-C₁₋₆ alkyl, -C₂₋₆ alkyl-NR^eR^f, -C(R^gR^h)-C₁₋₆ alkyl, -C(RⁱR^j)-aryl, -C(R^kR^l)-C₁₋₆ alkyl-aryl, -C(R^mRⁿ)-C₁₋₆ alkyl-heteroaryl, -C(R^oR^p)-C₁₋₆ alkyl-heterocyclil, -C₁₋₆ alkyl-O-C₁₋₆ alkyl-aryl, -C₁₋₆ alkyl-O-C₁₋₆ alkyl-heteroaryl, or -C₁₋₆ alkyl-O-C₁₋₆ alkyl-heterocyclil;

R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , and R^{21} independently represent hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, -CO- C_{1-6} alkyl, aryl, heteroaryl, heterocyclyl, - C_{1-6} alkyl- C_{3-8} cycloalkyl, - C_{1-6} alkyl-aryl, - C_{1-6} alkyl-heteroaryl, or - C_{1-6} alkyl-heterocyclyl;

R^a , R^c , R^e , R^f , R^g , R^h , R^i , R^j , R^k , R^l , R^m , R^n , R^o and R^p independently represent hydrogen, C_{1-6} alkyl, or C_{3-8} cycloalkyl;

R^b and R^d independently represent hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, - C_{1-6} alkyl-SO₂- C_{1-6} alkyl, or each combination of R^a and R^b , R^c and R^d , R^g and R^h , R^i and R^j , R^k and R^l and R^m and R^n together with the carbon atom to which they are attached may form a C_{3-8} cycloalkyl group;

R^{12} represents C_{1-6} alkyl or C_{3-8} cycloalkyl;

q represents 0 to 3;

optional substituents for alkyl groups of R^3 , R^4 , and R^5 include one or more halogen, C_{1-6} alkoxy, amino, cyano, or hydroxy groups;

and wherein said aryl, heteroaryl or heterocyclyl groups may be optionally substituted by one or more (i) C_{1-6} alkyl, (ii) halogen, (iii) -CF₃, (iv) -OCF₃, =O, (v) hydroxyl, (vi) C_{1-6} alkoxy, (vii) C_{2-6} alkynyl, (viii) C_{2-6} alkenyl, (ix) amino, (x) cyano, (xi) nitro, (xii) -NR²²COR²³, (xiii) -CONR²²R²³ - C_{1-6} alkyl-NR²²R²³ in which R²² and R²³ independently represent hydrogen or C_{1-6} alkyl, (xiv) - C_{1-6} alkyl-O- C_{1-6} alkyl, or (xv) - C_{1-6} alkanoyl groups;

or a pharmaceutically acceptable salt or solvate thereof.

10. (New) A compound according to claim 9 which is selected from the group consisting of:

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
(methanesulfonyl-phenyl-amino)-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
(ethanesulfonyl-phenyl-amino)-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
[(butane-1-sulfonyl)-phenyl-amino]-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
[phenyl-(propane-2-sulfonyl)-amino]-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
[methanesulfonyl-(4-trifluoromethyl-phenyl)-amino]-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
[methanesulfonyl-(3-methoxy-phenyl)-amino]-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
[methanesulfonyl-(4-methoxy-phenyl)-amino]-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
[methanesulfonyl-(2-methoxy-phenyl)-amino]-benzamide;

N-[(1S,2R)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
[(3,4-dichloro-phenyl)-methanesulfonyl-amino]-benzamide;

N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-[(3,5-dichloro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-[(2-cyano-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-[(4-cyano-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-[(2-chloro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-[(4-chloro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-[(3-cyano-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-[(3-chloro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3-cyano-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3-chloro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-(3-methoxy-phenyl)-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-(4-methoxy-phenyl)-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(4-chloro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3,5-dichloro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-pyridin-3-yl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-pyridin-2-yl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-pyridin-4-yl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-naphthalen-1-yl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-phenyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-cyclopropylamino-2-hydroxy-propyl)-(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-[1-(3-methoxy-phenyl)-1-methyl-ethylamino]-propyl]-[methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[methanesulfonyl-naphthalen-2-yl-amino)-benzamide;

N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(4-fluoro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3-fluoro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3,5-difluoro-phenyl)-methanesulfonyl-amino]-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-(1,5-dimethyl-hexylamino)-2-hydroxy-propyl]-{(methanesulfonyl-phenyl-amino)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-{(methanesulfonyl-phenyl-amino)-benzamide};
N-{(1*S*,2*R*)-1-Benzyl-3-[(1-ethyl-1*H*-pyrazol-4-ylmethyl)-amino]-2-hydroxy-propyl}-{(methanesulfonyl-phenyl-amino)-benzamide};
N-((1*S*,2*R*)-1-Benzyl-3-cyclohexylamino-2-hydroxy-propyl)-{(methanesulfonyl-phenyl-amino)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-{ethylamino-}{(methanesulfonyl-phenyl-amino)-benzamide};
N-[(1*S*,2*R*)-Benzyl-((S)-1-cyclohexylcarbamoyl-ethylamino)-hydroxy-propyl]-{(benzyl-methyl-amino)-}{(methanesulfonyl-phenyl-amino)-benzamide};
N-((1*S*,2*R*)-1-Benzyl-3-cyclohexylamino-2-hydroxy-propyl)-{(methanesulfonyl-phenyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-3-((S)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-{(methanesulfonyl-phenyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-{(methanesulfonyl-phenyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-3-(1,5-dimethyl-hexylamino)-2-hydroxy-propyl]-{(methanesulfonyl-phenyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-{(methanesulfonyl-phenyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-bromo-{(methanesulfonyl-phenyl-amino)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-ethynyl-{(methanesulfonyl-phenyl-amino)-benzamide};
(Methanesulfonyl-phenyl-amino)-methyl-biphenyl-3-carboxylic acid [(1*S*,2*R*)-1-benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-amide;
(Methanesulfonyl-phenyl-amino)-dimethyl-biphenyl-3-carboxylic acid [(1*S*,2*R*)-1-benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-amide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-cyclopentyl-{(methanesulfonyl-phenyl-amino)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-cyclohexyl-{(methanesulfonyl-phenyl-amino)-benzamide};
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-prop-1-ynyl-benzamide;

N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-
(methanesulfonyl-phenyl-amino)-nicotinamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-
(methanesulfonyl-phenyl-amino)-isonicotinamide;
N-[(1*S*,2*R*)-1-Benzyl-3-cyclopropylamino-2-hydroxy-propyl]-(methanesulfonyl-phenyl-
amino)-(2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethoxy-benzylamino)-propyl]-
(methanesulfonyl-phenyl-amino)-(2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-C-fluoro-
(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-fluoro-
(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-
(methanesulfonyl-phenyl-amino)-methylsulfanyl-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-
methanesulfonyl-(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-ethylsulfanyl-
(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-ethanesulfonyl-
(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-(*1*,*1*-
dioxo-*1*/*6*-isothiazolidin-2-yl)-(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-
(methanesulfonyl-phenyl-amino)-*N*'-*N*'-dipropyl-isophthalamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-ethoxy-
(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-cyano-
(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-
(methanesulfonyl-phenyl-amino)-C-methyl-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-
(methanesulfonyl-phenyl-amino)-methyl-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-chloro-
(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(4-fluoro-
phenyl)-methanesulfonyl-amino]-*(2*-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3-fluoro-
phenyl)-methanesulfonyl-amino]-*(2*-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3-methoxy-
phenyl)-methanesulfonyl-amino]-*(2*-oxo-pyrrolidin-1-yl)-benzamide;

N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3,4-difluoro-phenyl)-methanesulfonyl-amino]- (2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-
[methanesulfonyl-(4-methoxy-phenyl)-amino]- (2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3,5-difluoro-phenyl)-methanesulfonyl-amino]- (2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(4-cyano-phenyl)-methanesulfonyl-amino]- (2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3-cyano-phenyl)-methanesulfonyl-amino]- (2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-[(3-formamide-phenyl)-methanesulfonyl-amino]- (2-oxo-pyrrolidin-1-yl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-isobutyl-(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-Benzyl-hydroxy-(3-trifluoromethyl-benzylamino)-propyl]-3-(methanesulfonyl-phenyl-amino)-5-vinyl-benzamide;
N-[(1*S*,2*R*)-Benzyl-hydroxy-(3-trifluoromethyl-benzylamino)-propyl]- (methanesulfonyl-phenyl-amino)-(Z/E)-propenyl-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-3-(methanesulfonyl-phenyl-amino)-5-(2-methyl-propenyl)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-3-isopropenyl-5-(methanesulfonyl-phenyl-amino)-benzamide;
5-(Methanesulfonyl-phenyl-amino)-biphenyl-3-carboxylic acid [(1*S*,2*R*)-1-benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-amide;
N-[(1*S*,2*R*)-Benzyl-hydroxy-(3-trifluoromethyl-benzylamino)-propyl]-3-ethyl-5-(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-Benzyl-hydroxy-(3-trifluoromethyl-benzylamino)-propyl]-3-(methanesulfonyl-phenyl-amino)-5-propyl-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-3-isopropyl-5-(methanesulfonyl-phenyl-amino)-benzamide;
N-[(1*S*,2*R*)-1-Benzyl-3-((*S*)-1-cyclohexylcarbamoyl-ethylamino)-2-hydroxy-propyl]-3-(methanesulfonyl-phenyl-amino)-5-methylamino-benzamide;
Ethyl-(methanesulfonyl-phenyl-amino)-1*H*-indole-5-carboxylic acid [(1*S*,2*R*)-1-benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-amide; and
Ethyl-(methanesulfonyl-phenyl-amino)-1*H*-indole-5-carboxylic acid [(1*S*,2*R*)-1-benzyl-2-hydroxy-3-(trimethyl-hexylamino)-propyl]-amide;
or a pharmaceutically acceptable salt or solvate thereof.

11. (New) A pharmaceutical composition comprising a compound of claim 9 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.

12. (New) A pharmaceutical composition comprising a compound of claim 10 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.
13. (New) A method of treatment or prophylaxis of diseases characterised by elevated β -amyloid levels or β -amyloid deposits which comprises administering to a patient an effective amount of a compound of claim 9 or a pharmaceutically acceptable salt or solvate thereof.
14. (New) A method of treatment of prophylaxis of diseases characterized by elevated β -amyloid levels or β -amyloid deposits which comprises administering to a patient an effective amount of a compound of claim 10 or a pharmaceutically acceptable salt or solvate thereof.
15. (New) A pharmaceutical composition comprising a compound of claim 9 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of diseases characterised by elevated β -amyloid levels or β -amyloid deposits.
16. (New) A pharmaceutical composition comprising a compound of claim 10 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of diseases characterised by elevated β -amyloid levels or β -amyloid deposits.
17. (New) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 9 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.